Table 2: Changes in laboratory findings according to diabetes mellitus development during follow-up.
|
|
Diabetes Mellitus Developed |
|
Diabetes Mellitus Not – Developed |
|
Δp |
||||||
|
Variables |
Basal |
II. visit |
p |
|
Basal |
II. visit |
p |
|
|||
|
FBG (mg/dL) |
113.1±9.1 |
146.6±45.5 |
0.011* |
|
104.4±9.2 |
105.2±14.2 |
0.65 |
|
<0.001* |
||
|
HbA1c (%) |
6.1±0.6 |
6.8±0.7 |
0.589 |
|
5.7±1.1 |
5.8±0.4 |
0.969 |
|
0.386 |
||
|
Uric Acid (mg/dL) |
5.1 (3.8-7.2) |
5.0 (3.2-8.4) |
0.355 |
|
5.1 (2.3-10.9) |
5.2 (1.5-8.5) |
0.088 |
|
0.926 |
||
|
Total Bilirubin (mg/dL) |
0.5 (0.2-1.4) |
0.4 (0.2-1.1) |
0.463 |
|
0.5 (0.1-1.3) |
0.4 (0.1-1.1) |
0.082 |
|
0.090 |
||
|
Direk Bilirubin (mg/dL) |
0.1 (0.1-0.4) |
0.1 (0.1-0.4) |
0.241 |
|
0.1 (0.1-1.4) |
0.1 (0.1-1.1) |
0.27 |
|
0.731 |
||
Categorical variables were expressed as numbers and percentage, numerical variables were expressed as mean±standard deviation or median (min-max).
*p < 0.05 was considered statistically significant.
OAD: Oral Anti-diabetic Drug, OGTT: Oral Glucose Tolerance Test, FBG: Fasting Blood Glucose, PPG: Post Prandial Glucose, HbA1c: Glycosylated Hemoglobin